Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes

International Journal of COPD

Volumn 7, Issue , 2012, Pages 779-787

  Allen Ramey, Felicia C ^a   Gupta, Shaloo ^b   DiBonaventura, Marco daCosta ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b KANTAR HEALTH   (United States)

Author keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Emphysema; Health care resource use; Quality of life; Work productivity

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT;

ABSENTEEISM; ADULT; AGE DISTRIBUTION; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; ETHNIC DIFFERENCE; EXERCISE; FEMALE; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PRODUCTIVITY; QUALITY OF LIFE; SELF REPORT; SEX DIFFERENCE; UNITED STATES; WORK DISABILITY;

ABSENTEEISM; ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BRONCHITIS, CHRONIC; CHI-SQUARE DISTRIBUTION; COST OF ILLNESS; EFFICIENCY; EMERGENCY SERVICE, HOSPITAL; EMPLOYMENT; FEMALE; HEALTH CARE SURVEYS; HEALTH SERVICES; HEALTH STATUS; HOSPITALIZATION; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; QUALITY OF LIFE; SEX FACTORS; SICK LEAVE; SMOKING; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84872291772     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S35501     Document Type: Article

References (30)

1. Mannino DM. Chronic obstructive pulmonary disease: epidemiology and evaluation. Hosp Physician. 2001;37(10):22-31.
2. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124(2):474-481.
3. Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(5):507-513.
4. Izquierdo JL, Martin A, de Lucas P, et al. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis. 2010;5:241-249.
5. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstruc-tive pulmonary disease (updated 2010). Available from: http://www.goldcopd.org/uploads/users/files/globalinitiativeforobstructivelungdiseasereport_april112011.pdf. Accessed October 25, 2011.
7. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997;127(12):1072-1079.
8. Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56.
9. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic Euroquality of life five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117-1128.
10. DiBonaventura MD, Paulose-Ram R, Su J, et al. The impact of COPD on quality of life, productivity loss, and resource use among the elderly United States workforce. COPD. 2012;9(1):46-57.
11. DiBonaventura MD, Paulose-Ram R, Su J, et al. The burden of chronic obstructive pulmonary disease among employed adults. Int J Chron Obstruct Pulmon Dis. 2012;7:211-219.
12. Miravitlles M, Alvarez-Sala JL, Lamarca R, et al. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res. 2002;11(4):329-338.
13. Jones PW. Activity limitation and quality of life in COPD. COPD. 2007;4(3):273-278.
14. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2002;3(3): 219-228.
15. National Heart Lung and Blood Institute. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MS: National Institutes of Health; 2009.
16. Darkow T, Kadlubek PJ, Shah H, Phillips AL, Marton JP. A retro-spective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J Occup Environ Med. 2007;49(1):22-30.
17. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165(5):704-707.
18. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
19. Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11:43.
20. Kanervisto M, Saarelainen S, Vasankari T, et al. COPD, chronic bronchitis and capacity for day-to-day activities: negative impact of illness on the health-related quality of life. Chron Respir Dis. 2010;7(4):207-215.
21. Bolge SC, Doan JF, Kannan H, Baran RW. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res. 2009;18(4):415-422.
22. DiBonaventura M, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011;14(2):253-261.
23. Finkelstein EA, Allaire BT, Dibonaventura MD, Burgess SM. Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. J Occup Environ Med. 2011;53(9):1025-1029.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
25. Ware J Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12v2 Health Survey (with a supplement documenting version 1). Lincoln, RI: Quality Metric Incorporated; 2002.
26. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
27. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374(9691):733-743.
28. Vogelmeier C, Hederer B, Glabb T, et al. Tiotropium versus salme-terol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
29. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
30. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combina-tion with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-555.